Therapeutic Action
Bronchodilator, anticholinergic drug
PDF page 175
Loading InternPractice…
Drug reference
Bronchodilator, anticholinergic drug
PDF page 175
Severe asthma attack, in combination with salbutamol
PDF page 175
May cause: throat irritation, headache, cough, vomiting; anticholinergic effects: dryness of the mouth, constipation, dilation of the pupils, blurred vision, urinary retention, tachycardia. Administer with caution to older patients and patients with closed-angle glaucoma, urethro- prostatic disorders, urinary retention. Avoid or monitor combination with drugs known to have anticholinergic effects: tricyclic antidepressants (e.g. amitriptyline), first generation H-1 antihistamines (e.g. hydroxyzine, promethazine), biperiden, antispasmodics (e.g. atropine, hyoscine butylbromide), antipsychotics (e.g. chlorpromazine, haloperidol), etc. (increased risk of adverse effects). Pregnancy: no contra-indication Breast-feeding: no contra-indication
PDF page 175
Solution for inhalation, in unit dose vial of 0.25 mg in 1 ml (0.25 mg/ml) and 0.5 mg in 2 ml (0.25 mg/ml), to be administered via a nebuliser
PDF page 175
Child under 5 years: 0.25 mg (1 ml) per nebulisation every 20 minutes for the first hour Child 5 years and over and adult: 0.5 mg (2 ml) per nebulisation every 20 minutes for the first hour
PDF page 175
Volumes of nebuliser solution to be administered are insufficient to obtain efficient nebulisation in most nebulisers: add ipratropium to salbutamol and then 0.9% sodium chloride to obtain a total volume of 5 ml in the reservoir of the nebuliser. Stop the nebulisation when the reservoir is empty (after around 10 to 15 minutes).
PDF pages 175, 176
– Below 25 °C
PDF page 176
0.5 mg (2 ml) per nebulisation every 20 minutes for the first hour
PDF page 175